Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE CODEL (NOA-18)
2018-005027-16Phase 3Active
- Sponsor
- Heidelberg University Hospital
- Start
- May 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide, lomustine, procarbazine and vincristine in Oligodendroglioma (OG) and glioma (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Qualified overall survival. Started May 2020; status: active.
02
Drugs
temozolomidelomustineprocarbazinevincristine
03
Conditions
Oligodendroglioma (OG)glioma
Beyond the preview
Go deeper on 2018-005027-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-005027-16.